Document is current
Any future updates will be listed below
-
Authors
Graham, Robert J.
Amin, Reshma
Demirel, Nadir
Edel, Lisa
Lilien, Charlotte
MacBean, Victoria
Rafferty, Gerrard F.
Sawnani, Hemant
Schön, Carola
Smith, Barbara K.
Syed, Faiza
Sarazen, Micaela
Prasad, Suyash
Rico, Salvador
Perez, Geovanny F.
-
Funding
Funding for this research was provided by:
Astellas Gene Therapies
- License Information
-
More Information
Article History
Received: 13 February 2024
Accepted: 2 September 2024
First Online: 16 September 2024
Declarations
:
: Not applicable.
: Not applicable.
: Robert J. Graham reports consulting fees for trial design, outcomes assessments, and advisory board participation from Astellas Gene Therapies (formerly Audentes Therapeutics). Reshma Amin reports grant support from Canadian Institute of Health Research, Muscular Dystrophy Canada, Baxter Foundation, Boehringer-Ingelheim, VHS HomeHealthCare, Medigas, and Proresp; steering committee membership for Home Ventilation and Sleep Network: CHEST; and Scientific Officer for the Ontario Lung Health Foundation. Nadir Demirel reports travel reimbursement from Astellas Gene Therapies (formerly Audentes Therapeutics). Lisa Edel reports consulting fees from Roche, Biogen and Novartis; payment or honoraria from Sanofi, Roche and Neurology Academy; and travel reimbursement from Roche. Charlotte Lilien reports consulting fees, honoraria, funding for meeting-related travel, and/or advisory board participation from Astellas Gene Therapies (formerly Audentes Therapeutics), Roche, Biogen, Novartis, Sysnav, AFEHM, ATOM, Aparito and Scholar Rock. Victoria MacBean reports study funding, a research grant, and consulting fees to herself and to her institution from Astellas Gene Therapies (formerly Audentes Therapeutics). Gerrard F. Rafferty, Carola Schön and Faiza Syed report no competing interests relevant to this paper. Hemant Sawnani reports consulting fees for trial design, outcomes assessments, and advisory board participation from Astellas Gene Therapies (formerly Audentes Therapeutics). Barbara K. Smith reports prior research grant support from Astellas Gene Therapies (formerly Audentes Therapeutics). Micaela Sarazen is an employee of Astellas Gene Therapies (formerly Audentes Therapeutics). Suyash Prasad and Salvador Rico were employees and stockholders at Astellas Gene Therapies (formerly Audentes Therapeutics) at the time of this research. Geovanny F. Perez reports consulting fees and funding for meeting-related travel from Astellas Gene Therapies (formerly Audentes Therapeutics).
